🔴 Recursion Pharmaceuticals is trading 5.17% down in pre-market — no clear company-specific catalyst identified

Recursion Pharmaceuticals is trading 5.17% down at $3.32, with no clear company-specific catalyst identified.

• The decline reverses part of the August 19, 2026 rally, when shares closed at $3.50 after gaining 13.27%.
• The broader market is weaker, while biotechnology is higher in pre-market trading, so sector strength does not explain the decline.
• Recent company news centers on August 5 earnings and pipeline updates, rather than a new catalyst.